SAB Biotherapeutics (SABS) Times Interest Earned (2021 - 2026)
SAB Biotherapeutics' (SABS) quarterly Times Interest Earned came in at -$0.73 in Q1 2026, up 98.24% YoY from -$0.37 in Q1 2025, and up 99.71% on a QoQ basis from -$253.01 in Q4 2025.
SAB Biotherapeutics (SABS) Times Interest Earned (2021 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 6 years of Times Interest Earned data on file, last reported at -$0.73 in Q1 2026.
- Quarterly Times Interest Earned rose 98.24% year-over-year to -$0.73 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.11 (up 98.7% YoY) and the FY2025 annual result came in at -$1.88, up 94.81% from the prior year.
- Times Interest Earned improved to -$0.73 in Q1 2026, from -$253.01 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $33.58 in Q4 2024 to a low of -$253.01 in Q4 2025.
- A 5-year average of -$45.92 and a median of -$21.57 in 2022 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned sank 2062.85% — and 2024, when it jumped 113.86%.
- Tracing SABS's Times Interest Earned over 5 years: stood at $12.35 in 2022, then slumped by 2062.85% to -$242.35 in 2023, then jumped by 113.86% to $33.58 in 2024, then plunged by 853.41% to -$253.01 in 2025, then jumped by 99.71% to -$0.73 in 2026.
- The last three Times Interest Earned figures came in at -$0.73 (Q1 2026), -$253.01 (Q4 2025), and -$17.4 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | -0.80 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.80 |
| Mar 31, 2026 | -0.73 |
| Dec 31, 2025 | -253.01 |
| Sep 30, 2025 | -17.40 |
| Jun 30, 2025 | -13.36 |
| Mar 31, 2025 | -41.26 |
| Dec 31, 2024 | 33.58 |
| Sep 30, 2024 | -43.33 |
| Jun 30, 2024 | -41.47 |
| Mar 31, 2024 | -48.24 |
| Dec 31, 2023 | -242.35 |
| Sep 30, 2023 | -12.16 |
| Jun 30, 2023 | -3.90 |
| Mar 31, 2023 | -62.73 |
| Dec 31, 2022 | 12.35 |
| Sep 30, 2022 | -22.06 |
| Jun 30, 2022 | -3.05 |
| Mar 31, 2022 | -21.57 |
| Dec 31, 2021 | -110.81 |
| Sep 30, 2021 | -14.00 |